降脂利肝颗粒联合辛伐他汀治疗非酒精性脂肪肝的临床疗效观察

摘要

Objective To investigate the clinical efifcacy of Jiangzhiligan granules combined with simvastatin in the treatment of non-alcoholic fatty liver disease (NAFLD).Methods 86 patients with NAFLD from January 2014 to December 2015 in our hospital were selected and divided into control group (43 cases) and research group (43 cases) by the random number table method. Patients in the control group were given simvastatin tablets, while the research group was treated with the supplementary Jiangzhiligan granules. The treatment course of the two groups was both 3 months. The changes of liver biochemical indexes and serum lipid before and after the treatment were observed, the clinical efifcacy of the two groups was evaluated.ResuIts Compared with the levels before treatment, the ALT, AST, GGT in both of the two groups decreased signiifcantly after 3 months treatment, and the changes of the observation group were more obvious, the difference was statistically signiifcant (P < 0.05). The TG, TC, LDL-C in both of the two groups decreased signiifcantly, and the HDL-C increased signiifcantly after treatment, the changes of the research group were more obvious, the difference was statistically signiifcant (P < 0.05). The SOD in both of the two groups increased signiifcantly, and the MDA decreased signiifcantly after treatment, the changes of the research group were more obvious, the difference was statistically signiifcant (P < 0.05). The total effective rate in the observation group was 90.70%, which was signiifcantly higher than that in the control group of 72.09%, the difference was statistically signiifcant (P <0.05). No adverse reactions were found in the two groups after treatment, and the safety was good.ConcIusion Jiangzhiligan granules combined with simvastatin can signiifcantly improve liver biochemical indexes and serum lipid of patients with NAFLD, and has good safety and clinical value.%目的 探讨降脂利肝颗粒联合辛伐他汀治疗非酒精性脂肪肝(NAFLD)的临床疗效.方法 选取2014年1月至2015年12月我院收治的86例NAFLD患者作为研究对象,通过随机数字表法分为对照组和研究组各43例.对照组给予口服辛伐他汀片治疗,研究组在对照组治疗方案的基础上加用降脂利肝颗粒治疗,疗程均为3个月.观察治疗前后两组患者的肝生化指标和血脂水平的变化,评价两组治疗的临床疗效.结果 治疗3个月后,两组患者的ALT、AST、GGT水平均较治疗前下降,研究组下降更为明显,差异有统计学意义(P<0.05).两组患者经治疗后的TG、TC、LDL-C水平均较治疗前下降,HDL-C较治疗前升高,研究组变化更为明显,差异有统计学意义(P<0.05).两组患者经治疗后的SOD活力明显升高,MDA水平明显下降,且研究组变化更为明显,差异有统计学意义(P<0.05).研究组临床总有效率(90.70%)明显高于对照组(72.09%),差异有统计学意义(P<0.05).两组患者治疗后均未见不良反应发生,安全性较好.结论 降脂利肝颗粒联合辛伐他汀可以明显改善NAFLD患者的肝生化指标和血脂代谢,且安全性较好,具有临床推广价值.